Impact of pembrolizumab (pembro) versus paclitaxel on health-related quality of life (HRQoL) in patients with advanced gastric or gastroesophageal junction (GEJ) cancer that has progressed after first-line chemotherapy (KEYNOTE-061)

被引：0
|
作者：
Van Cutsem, E. [1 ,2 ]
Amonkar, M. [3 ]
Fuchs, C. S. [4 ]
Alsina, M. [5 ,6 ]
Ozguroglu, M. [7 ]
Bang, Y-J. [8 ]
Chung, H. C. [9 ]
Muro, K. [10 ]
Goekkurt, E. [11 ]
Benson, A. [12 ]
Sun, W. [13 ]
Wainberg, Z. A. [14 ]
Norquist, J. [3 ]
Chen, X. [3 ]
Shih, C-S. [3 ]
Shitara, K. [15 ]
机构：
[1] Univ Hosp Gasthuisberg Leuven, Digest Oncol, Leuven, Belgium
[2] Katholieke Univ Leuven, Leuven, Belgium
[3] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA
[4] Yale Canc Ctr, Med Oncol, New Haven, CT USA
[5] Vall dHebron Univ Hosp, Med Oncol, Barcelona, Spain
[6] Univ Autonoma Barcelona, Inst Oncol VHIO, Barcelona, Spain
[7] Istanbul Univ Cerrahpasa, Clin Trial Unit, Cerrahpasa Sch Med, Internal Med,Med Oncol, Istanbul, Turkey
[8] Seoul Natl Univ, Internal Med, Coll Med, Seoul, South Korea
[9] Yonsei Univ, Med Oncol, Coll Med, Yonsei Canc Ctr, Seoul, South Korea
[10] Aichi Canc Ctr Hosp, Clin Oncol, Nagoya, Aichi, Japan
[11] Univ Canc Ctr Hamburg, HOPE, North German Trial Ctr Innovat Oncol NIO, Hamburg, Germany
[12] Northwestern Med Fac Fdn, Hematol Oncol, Chicago, IL USA
[13] Univ Kansas, Internal Med, Med Oncol, Westwood, KS USA
[14] Univ Calif Los Angeles, David Geffen Sch Med, Med Hematol & Oncol, Los Angeles, CA 90095 USA
[15] Natl Canc Ctr Hosp, Gastrointestinal Oncol, Chiba, Japan
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
791P
引用
收藏
页码：304 / 304
页数：1
相关论文
共 50 条
  • [31] Self-reported health-related quality of life predicts survival for patients with advanced gastric cancer treated with first-line chemotherapy
    Se Hoon Park
    Moon Sook Cho
    Young Saing Kim
    Junshik Hong
    Eunmi Nam
    Jinny Park
    Eun Kyung Cho
    Dong Bok Shin
    Jae Hoon Lee
    Woon Kee Lee
    Quality of Life Research, 2008, 17 : 207 - 214
  • [32] First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced gastroesophageal junction cancer (GEJC) and esophageal adenocarcinoma (EAC): Analysis of KEYNOTE-590 and KEYNOTE-859 by tumor type.
    Shiu, Kai-Keen
    Rivera, Fernando
    Medley, Louise C.
    Aghmesheh, Morteza
    Dunne, Richard Francis
    Roy, Rajarshi
    Wyrwicz, Lucjan S.
    Larson, Timothy
    Metges, Jean-Philippe
    Mansoor, Wasat
    Goekkurt, Eray
    Moreira Antunes, Luiz Carlos
    Castro Oliden, Victor
    Jensen, Erin
    Shah, Sukrut
    Bordia, Sonal
    Bhagia, Pooja
    Lowery, Maeve Aine
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 345 - 345
  • [33] Health-related quality of life (HRQoL) in the KEYNOTE-045 study of pembrolizumab versus investigator-choice chemotherapy for previously treated advanced urothelial cancer.
    Vaughn, David J.
    Bellmunt, Joaquim
    De Wit, Ronald
    Fradet, Yves
    Lee, Jae-Lyun
    Fong, Lawrence
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [34] Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
    Xu, Rui-hua
    Arkenau, Hendrik-Tobias
    Bang, Yung-Jue
    Denlinger, Crystal S.
    Kato, Ken
    Tabernero, Josep
    Wang, Jin
    Li, Jiang
    Castro, Henry
    Moehler, Markus H.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [35] Health-related quality-of-life analysis from KEYNOTE-590: pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer
    Mansoor, Wasat
    Joo, Seongjung
    Norquist, Josephine M.
    Kato, Ken
    Sun, Jong-Mu
    Shah, Manish A.
    Enzinger, Peter
    Adenis, Antoine
    Doi, Toshihiko
    Kojima, Takashi
    Metges, Jean-Philippe
    Li, Zhigang
    Kim, Sung-Bae
    Cho, Byoung Chol
    Sunpaweravong, Patrapim
    Maqueda, Maria Alsina
    Goekkurt, Eray
    Suryawanshi, Shailaja
    Shah, Sukrut
    Shen, Lin
    ONCOLOGIST, 2024, 29 (10): : e1324 - e1335
  • [36] Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple negative breast cancer
    Schmid, P.
    Haiderali, A.
    Mejia, J.
    Guo, Z.
    Zhou, X.
    Martin-Nguyen, A.
    Cortes, J.
    Winer, E.
    ANNALS OF ONCOLOGY, 2020, 31 : S65 - S66
  • [37] Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
    Bang, Yung-Jue
    Kang, Yoon-Koo
    Catenacci, Daniel V.
    Muro, Kei
    Fuchs, Charles S.
    Geva, Ravit
    Hara, Hiroki
    Golan, Talia
    Garrido, Marcelo
    Jalal, Shadia I.
    Borg, Christophe
    Doi, Toshihiko
    Yoon, Harry H.
    Savage, Mary J.
    Wang, Jiangdian
    Dalal, Rita P.
    Shah, Sukrut
    Wainberg, Zev A.
    Chung, Hyun Cheol
    GASTRIC CANCER, 2019, 22 (04) : 828 - 837
  • [38] Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
    Yung-Jue Bang
    Yoon-Koo Kang
    Daniel V. Catenacci
    Kei Muro
    Charles S. Fuchs
    Ravit Geva
    Hiroki Hara
    Talia Golan
    Marcelo Garrido
    Shadia I. Jalal
    Christophe Borg
    Toshihiko Doi
    Harry H. Yoon
    Mary J. Savage
    Jiangdian Wang
    Rita P. Dalal
    Sukrut Shah
    Zev A. Wainberg
    Hyun Cheol Chung
    Gastric Cancer, 2019, 22 : 828 - 837
  • [39] A randomized, double-blind, phase III study of pembrolizumab plus chemotherapy as first-line therapy in patients with HER2-negative, advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859
    Qin, S.
    Tabernero, J.
    van Cutsem, E.
    Fuchs, C. S.
    Janjigian, Y. Y.
    Bhagia, P.
    Li, K.
    Adelberg, D.
    Bang, Y-J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1316 - S1317
  • [40] FUNCTIONALITY AND HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS OVER 70 YEARS OF AGE WHO ARE CANDIDATES FOR FIRST-LINE CHEMOTHERAPY TREATMENT
    Fiallo, Suarez Dolly Viviana
    Carrillo, Quesada Macarena
    Lemes, Castellano Angelina
    Veiga, Vaz Alvaro
    Cruz, Cruz Naylen
    Rodriguez, Medina Carlos
    Suarez, Cabrera Alexia
    Luzardo, Henriquez Hugo
    Gonzalvez, Fernandez Joan
    Gonzalez, Martin Jesus Maria
    Fernandez-Caldas, Gonzalez Paula
    De la Iglesia, Inigo Silvia
    Gomez, Casares Maria Teresa
    Molero, Labarta Teresa
    HAEMATOLOGICA, 2020, 105 : 319 - 320
12345